SCiP (Spinal Cord Innovation in Pediatrics) is a non-invasive spinal electrical neuromodulation device developed by SpineX to treat cerebral palsy in children.
Cerebral palsy is the most prevalent childhood motor condition, affecting 1 in 345 children worldwide, with a high prevalence in the United States. It is disabling and incurable.
Every year, around 10,000 new cases of cerebral palsy are diagnosed as a result of injury to the developing brain. It has an impact on a person's capacity to move, as well as their ability to maintain balance and posture.
There are currently no techniques or drugs available to prevent or treat CP. More frequently than not, children with CP are left to undergo permanent invasive procedures to reduce stiffness, which is a prevalent sign of the disorder.
SCiP uses transcutaneous spinal cord stimulation to address underlying neurological dysfunction in children with cerebral palsy.
SCiP promises to be the first medical device in the United States to cure CP by transforming the brain and spinal cord dysfunctional connectivity into highly functional systems, and early clinical feasibility trials have shown considerable promise.
SCiP aims to be the first medical device in the U.S. to treat CP by transforming the brain and spinal cord dysfunctional connectivity into highly functional systems, having shown great promise in early clinical feasibility studies.
SpineX is developing spinal neuromodulation as a platform technology, and SCiP is the company's second Breakthrough Device Designation, following the SCONETM device, which was recognized for Neurogenic Bladder.